Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3.
The hormone 1 alpha, 25 dihydroxyvitamin D3 (1,25(OH)2D3) has potent immunosuppressive effects in vitro. Recent publications also described a protective effect of the hormone in various animal models of immune-mediated diseases. To test its in vivo activity we induced active Heymann nephritis in Lewis rats that were either untreated or treated with 1,25(OH)2D3 or its synthetic 20-epi analogue, KH1060. Treatment with cyclosporine A (CsA) was used as an immunosuppressive control. In this nephrotic model the administration of 1,25(OH)2D3 (0.5 microgram/kg body weight) given on alternate days during the first 13 days after active immunization significantly reduced the proteinuria as measured by weeks 7-9. This reduction was comparable to the reduction observed in rats treated with CsA (20 mg/kg) on alternate days. A second series of experiments with 1,25(OH)2D3 confirmed these findings. The level of autoantibodies was found to be significantly suppressed during the treatment time in the CsA (20 mg/kg) group, whereas the limit of significance (P = 0.06) was reached in the 1,25(OH)2D3 (0.5 microgram/kg) group. The size of the immune deposits also was found to be substantially smaller in the groups that developed less proteinuria. The administration of 1,25(OH)2D3 transiently increased the mean serum calcium concentration with 2.5 mg/dl above the pretreatment values, and the urinary calcium excretion by a factor of 3-5 during the short treatment time. Treatment with the analogue KH1060 did not reduce the proteinuria significantly. Our experiments add evidence to the hypothesis that 1,25(OH)2D3 in pharmacological doses has immunosuppressive potency.
Branisteanu
D D
DD
Laboratorium Experimentele Geneeskunde en Endocrinologie, University Hospital, Katholieke Universiteit Leuven, Belgium.
Leenaerts
P
P
van Damme
B
B
Bouillon
R
R
D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D002117:Calcitriol / Q000031:analogs & derivatives / Q000276:immunology / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000276:immunology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew
D001323:Autoantibodies; D007166:Immunosuppressive Agents; C074279:KH 1060; D016572:Cyclosporine; D003404:Creatinine; D002117:Calcitriol; D002118:Calcium